| Controlled branching of polyglycidol and formation of protein–glycidol bioconjugates via a graft-from approach with “PEG-like” arms BR Spears, J Waksal, C McQuade, L Lanier, E Harth Chemical Communications 49 (24), 2394-2396, 2013 | 48 | 2013 |
| Surveillance after resection of vestibular schwannoma: measurement techniques and predictors of growth S Tang, AS Griffin, JA Waksal, CD Phillips, CE Johnson, JP Comunale, ... Otology & Neurotology 35 (7), 1271-1276, 2014 | 23 | 2014 |
| Comparing outcomes between liposomal daunorubicin/cytarabine (cpx-351) and hma+ venetoclax as frontline therapy in acute myeloid leukemia J Grenet, AG Jain, M Burkart, J Waksal, C Famulare, Y Numan, M Stahl, ... Blood 138, 32, 2021 | 16 | 2021 |
| Novel therapeutics and targets in myelofibrosis JA Waksal, CN Harrison, JO Mascarenhas Leukemia & Lymphoma 63 (5), 1020-1033, 2022 | 13 | 2022 |
| Telomerase-targeted therapies in myeloid malignancies JA Waksal, C Bruedigam, RS Komrokji, CHM Jamieson, JO Mascarenhas Blood Advances 7 (16), 4302-4314, 2023 | 12 | 2023 |
| Clinical utility of fedratinib in myelofibrosis JA Waksal, D Tremblay, J Mascarenhas OncoTargets and therapy, 4509-4521, 2021 | 9 | 2021 |
| Novel therapies in myelofibrosis: beyond JAK inhibitors JA Waksal, J Mascarenhas Current Hematologic Malignancy Reports 17 (5), 140-154, 2022 | 8 | 2022 |
| Safety and efficacy of CPX-351 in younger patients< 60 years old with secondary acute myeloid leukemia: an updated analysis A Przespolewski, AD Goldberg, C Talati, S Fazal, P Vachhani, ... Blood 138, 1264, 2021 | 5 | 2021 |
| Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia H Fruchtman, ZM Avigan, JA Waksal, N Brennan, JO Mascarenhas Leukemia, 1-9, 2024 | 3 | 2024 |
| Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges HO Ajufo, JA Waksal, JO Mascarenhas, RK Rampal Therapeutic Advances in Hematology 14, 20406207231177282, 2023 | 3 | 2023 |
| Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective JA Waksal, MS Tallman Leukemia & lymphoma 62 (4), 779-790, 2021 | 3 | 2021 |
| Safety and efficacy of CPX-351 in younger patients (< 60 years old) with secondary acute myeloid leukemia A Przespolewski, AD Goldberg, C Talati, S Fazal, P Vachhani, ... Blood 141 (12), 1489-1493, 2023 | 2 | 2023 |
| Contemporary and future strategies in polycythemia vera JA Waksal, DA Tremblay Best Practice & Research Clinical Haematology 35 (2), 101370, 2022 | 2 | 2022 |
| A novel application of XPO1 inhibition for the treatment of myelofibrosis M Metzger, ZM Avigan, P Vachhani, J Waksal, J Mascarenhas Blood Neoplasia 1 (2), 100010, 2024 | | 2024 |
| Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera JA Waksal, NE Wagner, JO Mascarenhas Risk 22 (1), 2024 | | 2024 |
| Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera J Waksal, R Hoffman, A Yacoub, F Passamonti, AT Gerds, V Gupta, ... Blood 142, 3187, 2023 | | 2023 |
| Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis D Tremblay, ZI Schwabkey, YJRA Riazat-Kesh, G Van Hyfte, NH Al Ali, ... Blood 142, 1830, 2023 | | 2023 |
| LIVER BIOPSY IS NECESSARY IN PATIENTS WITH HEMATOLOGICAL DISORDERS AND ABNORMAL LIVER CHEMISTRY TESTS IN ORDER TO EXCLUDE NOT ONLY DRUG-INDUCED LIVER INJURY BUT ALSO … P Li, JA Waksal, D Tremblay, TD Schiano, MI Fiel HEPATOLOGY 76, S1458-S1459, 2022 | | 2022 |
| Synthesis of polyglycidols with linear and controlled branched structures: Study of the reaction kinetics and postmodification into nanosponges as drug delivery systems BR Spears, J Waksal, BP McGrath, E Harth ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 244, 2012 | | 2012 |
| Nanoformulation and controlled release with" nanosponge" delivery systems: The importance of the tailored nanonetwork DM Stevens, BR Spears, G Hariri, JN Dobish, J Waksal, H Watson, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 244, 2012 | | 2012 |
